Europe Sterile Injectables Cdmo Market Size & Outlook
Related Markets
Europe sterile injectables cdmo market highlights
- The Europe sterile injectables cdmo market generated a revenue of USD 918.8 million in 2024.
- The market is expected to grow at a CAGR of 9.7% from 2025 to 2030.
- In terms of segment, large molecule was the largest revenue generating molecule type in 2024.
- Large Molecule is the most lucrative molecule type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 918.8 million |
| Market revenue in 2030 | USD 1,605.1 million |
| Growth rate | 9.7% (CAGR from 2025 to 2030) |
| Largest segment | Large molecule |
| Fastest growing segment | Large Molecule |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | Boehringer Ingelheim, Baxter International Inc, Vetter Pharma-Fertigung, Recipharm, Fresenius Kabi, Ajinomoto, PCI Pharma Services, IDT Biologika, Alcami, Fareva, Eurofins Scientific SE, Siegfried Holding AG |
Other key industry trends
- In terms of revenue, Europe region accounted for 21.6% of the global sterile injectables cdmo market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,008.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sterile Injectables CDMO Market Scope
Sterile Injectables CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Torbay Council | View profile | 1001-5000 | Torquay, Torbay, United Kingdom, Europe | https://www.torbay.gov.uk/ |
| Famar | View profile | 1001-5000 | Athens, Attiki, Greece, Europe | https://www.famar-group.com |
| Aenova Group | View profile | 5001-10000 | Greensboro, North Carolina, United States, North America | http://www.aenova-group.com |
| Fareva | View profile | 5001-10000 | Tournon-sur-rhône, Rhone-Alpes, France, Europe | http://www.fareva.com/ |
| Pfizer CentreOne | View profile | - | New York, New York, United States, North America | https://www.pfizercentreone.com |
| IDT Biologika | View profile | 1001-5000 | Dessau, Sachsen-Anhalt, Germany, Europe | https://idt-biologika.de/ |
| Ajinomoto | View profile | 10001+ | Tokyo, Tokyo, Japan, Asia | http://www.ajinomoto.com |
| Fresenius Kabi | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://www.fresenius-kabi-oncology.com/ |
| Unither Pharmaceuticals | View profile | 1001-5000 | Paris, Ile-de-France, France, Europe | https://www.unither-pharma.com/ |
| PCI Pharma Services | View profile | 1001-5000 | Philadelphia, Pennsylvania, United States, North America | http://www.pciservices.com |
| Alcami | View profile | 501-1000 | Wilmington, North Carolina, United States, North America | http://www.alcaminow.com |
| Vetter Pharma-Fertigung | View profile | 5001-10000 | Ravensburg, Baden-Wurttemberg, Germany, Europe | https://www.vetter-pharma.com/en |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Baxter International Inc | View profile | 60000 | One Baxter Parkway, Deerfield, IL, United States, 60015 | https://www.baxter.com |
Europe sterile injectables cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sterile injectables cdmo market will help companies and investors design strategic landscapes.
Large molecule was the largest segment with a revenue share of 66.02% in 2024. Horizon Databook has segmented the Europe sterile injectables cdmo market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Europe has a robust pharmaceutical sector with numerous drug discoveries, development, and manufacturing companies. The growing number of pharmaceutical activities is anticipated to increase the demand for CDMOs. Moreover, the growing trend of outsourcing services to European countries is expected to contribute to the growing demand for sterile injectables CDMO.
The market is expected to be driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders & rare diseases, the presence of established pharmaceutical & biopharmaceutical companies, rising demand for biologics & biosimilars, which require specialized filling and packaging processes, and the expansion of new facilities.
Similarly, the trend of drug discovery, along with emerging R&D activities, is changing market scenarios at a rapid rate. Furthermore, significant investments are being made to enhance manufacturing capabilities within the region.
Reasons to subscribe to Europe sterile injectables cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe sterile injectables cdmo market databook
-
Our clientele includes a mix of sterile injectables cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe sterile injectables cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe sterile injectables cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe sterile injectables cdmo market size, by country, 2018-2030 (US$M)
Europe Sterile Injectables CDMO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
